Clinical trials: Plasma
Knee Chondropathy, Osteoarthritis, Knee
Platelet-rich Plasma vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology
The investigators hypothesized that intra-articular injections of Platelet-rich Plasma (PRP) to treat knee degenerative articular cartilage pathology could determine pain relief and recovery of knee function with overall clinical…
- Trial name
- PRP2009 (NCT01670578)
- Testing
- PRP, Hyaluronic acid
- Where
- Italy
- Volunteers
- 192 people
- Sponsor
- Istituto Ortopedico Rizzoli
Multiple Myeloma and Plasma Cell Neoplasm
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with relapsed…
- Trial name
- NCT00002907
- Testing
- bryostatin 1
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Trigeminal Neuralgia, Blood
Transcriptome Sequencing Analysis of Whole Blood From Patients With Trigeminal Neuralgia
Trigeminal neuralgia is a type of neuropathic pain that brings great physical and psychological pressure to patients. Chronic pain can cause changes in the composition of central and peripheral body fluids, and these changes may…
- Conditions
- Trigeminal Neuralgia, Blood, Plasma, Cerebrospinal Fluid
- Trial name
- NCT04923399
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for…
- Trial name
- NCT02780609
- Testing
- Selinexor, Melphalan, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hodgkin's Lymphoma, Mature T-cell Lymphoma
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
The study hypothesis is that lenalidomide and romidepsin (and dexamethasone for patients with myeloma) will have an acceptable toxicity profile and that in combination will have sufficient activity in the target population…
- Conditions
- Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
- Trial name
- RID (NCT01742793)
- Testing
- lenalidomide (Revlimid) and romidepsin (Istodax)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Multiple Myeloma (MM)
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
- Trial name
- NCT02211014
- Testing
- acalabrutinib
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Acerta Pharma BV
Smoking
Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum
The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three electronic cigarettes versus…
- Trial name
- NCT02269514
- Testing
- Own Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- R.J. Reynolds Vapor Company
Human Immunodeficiency Virus-type 1 Infection
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid…
- Trial name
- SALIF (NCT01709084)
- Testing
- Rilpivirine, Efavirenz, Tenofovir disoproxil fumarate
- Where
- 18 sites in Cameroon, Kenya and 4 more
- Volunteers
- 426 people
- Sponsor
- Janssen-Cilag International NV
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years.
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change
- Trial name
- ALPS (NCT05138848)
- Testing
- Time in Bed Restriction, Sleep Schedule
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Genitourinary Syndrome of Menopause
Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit
This study is a randomized, controlled, non-inferiority trial, that will be performed on 192 women on Menopause (absence of menstruation for at least 12 months), with diagnostic of genitourinary syndrome of menopause (SGM) and a…
- Trial name
- CellularMatrix (NCT06425978)
- Testing
- Cellular Matrix / A-CP-HA Kit, Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)
- Where
- Spain
- Volunteers
- 192 people
- Sponsor
- Fundación Santiago Dexeus Font
Multiple Myeloma
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
- Trial name
- NCT01720043
- Testing
- Velcade
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Coronavirus, Coronavirus Infection
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study
Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases.
- Trial name
- CP-COVID-19 (NCT04332835)
- Testing
- Plasma, Standard Therapy
- Where
- Colombia
- Volunteers
- 92 people
- Sponsor
- Universidad del Rosario
Myeloma
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
The goal of this clinical research study is to learn if carfilzomib and vorinostat combined with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control multiple myeloma (MM).
- Trial name
- NCT02114502
- Testing
- Carfilzomib, SAHA, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center
Herpes Zoster (HZ)
Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia
The investigators' objectives are to examine the longitudinal association of obesity and obesity-related factors and risk of incident herpes zoster (HZ), also known as shingles, and the longitudinal association of obesity and…
- Trial name
- NCT06638177
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Waldenstrom Macroglobulinemia
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally.
- Trial name
- RAINBOW (NCT04061512)
- Testing
- Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
- Where
- 25 sites in United Kingdom
- Volunteers
- 148 people
- Sponsor
- University College, London
Myeloma, Plasma-Cell, Myeloma-Multiple
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Background: T cells are white blood cells that fight several cancers. One cancer therapy involves removing a persons' T cells, changing them in a lab, and then returning them to the person.
- Trial name
- NCT02215967
- Testing
- Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT05972577
- Testing
- Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center